ERBB2 and neoplasm: Especially patients with HR-positive, HER2-negative metastatic disease resistant to endocrine-based therapy and not requiring rapid tumor response are generally suitable for MCT (Cazzaniga et al., 2019[12]; Krajnak et al., 2022[24]).